canakinumab
Novartis
['canakinumab']
canakinumab as adjuvant approach presented at esmo with no benefit in primary endpoint presented at esmo! 
I am Executive Director at the  Center for Thoracic Oncology at Mount Sinai Hospital , NYC and Professor of Medicine at Icahn Medical School at Mount Sinai, NY